Third Annual Cardiotoxicity and Drug Safety
Loews Philadelphia Hotel
1200 Market Street
Philadelphia, Pennsylvania 19107
Keywords: Cardiotoxicity and Drug Safety, Cambridge Healthtech Institute, Loews Philadelphia Hotel

Schedule of Presentations:

Tuesday, June 9, 2009
07:30:00 Morning Coffee
07:30:00 Registration Open
07:30:00 Check-In
08:30:00 Chairperson’s Remarks Gary A. Gintant
08:40:00 Introductory Overview of Cardiac Safety Assessments J. Rick Turner
09:10:00 Testing Drug-Induced Inhibition of hERG: How Voltage and Inactivation Makes a Difference Harry Witchel
09:40:00 Value of Animals with Failing Heart and/or Ventricular Hypertrophy for Increasing Ability to Detect Cardiovascular Effects of Drugs Anusak Kijtawornrat
10:10:00 Networking Coffee Break
10:40:00 Strategy for Preclinical Cardiovascular Safety Evaluation for Biologicals Hugo Vargas
11:10:00 Developing and Using a Scientific-Based Integrated Risk Assessment for Managing Drug Candidates in Early Development Peter K.S. Siegl
11:40:00 Challenges of the Integrative Risk Assessment, the “Heart” of Preclinical Cardiac Safety Evaluations Gary A. Gintant
12:10:00 Luncheon Presentation
12:10:00 The Yin and Yang in Label Free Measurement - Monitoring of Cor.At pure Cardiomyocytes on the xCelligence Platform to Reveal Clinical Relevant Drug Behaviour Heribert Bohlen
12:40:00 Luncheon Presentation
12:40:00 Unique Access to Preclinical, Clinical and Post-Market Data Sources to Assess Candidates and Advance Drug Development Philip MacLaughlin
13:10:00 Session Break
13:40:00 Chairperson’s Remarks J. Rick Turner
13:45:00 Using Ex-vivo and In-vivo Assays for Assessing Cardiotoxicities Beyond Ionic Channels Huabin Sun
14:15:00 Talk Title to be Announced CRAIG T JANUARY
14:45:00 Inward Rectifier Kir2.1 PatchXpress Assay as a Model of Cardiac IK1 John P. Imredy
15:00:00 Grand Opening Refreshment Break in the Exhibit Hall
15:40:00 Use of Cardiac Troponin Measurements in Drug Development For the Detection of Cardiotoxicity John K. Finkle
16:10:00 In Vitro and In Vivo Models to Predict Cardiotoxicity: Where do we Stand? Thomas Force
16:40:00 Cardiotoxicity of Anti-Cancer Drugs: A Matter of Multiple Hits Giorgio Minotti
17:10:00 Happy Hour in the Exhibit Hall
18:10:00 End of Day
Wednesday, June 10, 2009
07:30:00 Continental Breakfast Breakout Discussions Table Seven: In Vitro and In Vivo Models to Predict Cardiotoxicity Thomas Force
07:30:00 Registration Open
07:30:00 Check-In
08:00:00 Table Eight: New Insights Into Clinical Cardiac Safety Testing Sashi Nadanaciva
08:10:00 Table Nine: Cardiac Safety Assessments: A Regulatory Perspective Colette Strnadova
08:30:00 Chairperson’s Remarks Philip Sager
08:40:00 Post-Hoc Comparison of Alternative Analytical Methods in the Non-Inferiority Comparison of Drug to Placebo in a thorough QT Study Charles M. Beasley
09:10:00 Using Preclinical QT Data to Impact Clinical Study Design and Decision Making and Clinical Validation of Preclinical Models Philip Sager
09:40:00 Sponsored Presentation (Opportunity Available)
09:40:00 Sponsored Presentation (Opportunity Available)
10:10:00 Networking Coffee Break in the Exhibit Hall
10:50:00 Cardiac Safety Assessments for Oncology Drugs: A Regulatory Perspective Colette Strnadova
11:20:00 Improving Safety in Medical Products Wendy Sanhai
11:50:00 Critical Path Meets Cardiac Safety: A Novel, Collaborative Paradigm for Cardiac Safety Evaluation Mitchell W. Krucoff
12:20:00 Close of Cardiotoxicity and Drug Safety Conference
12:25:00 End of Day
13:00:00 Discussion
13:00:00 Chairperson’s Remarks
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.